KIT and gastrointestinal stromal tumor: Nonetheless, recent research showed that the majority of patients with advanced KIT mutated GIST with resistance to treatment with imatinib had 1–3 KIT mutations and only 17% showed substantial heterogeneity with 4–14 KIT mutations detected in plasma [30].